Drug Approval | January 28, 2022
European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
Philips expands remote cardiac monitoring portfolio with patch-based, clinical-grade ECG designed to improve patient recruitment, compliance and retention by reducing need for site visits during clinical trials
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
The tablet donations provided for the treatment of more than 600 million schoolchildren in affected countries in sub-Saharan Africa since 2007
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Subscribe To Our Newsletter & Stay Updated
